Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-11-2017 | Original Article

¹⁸F-Florbetaben PET beta-amyloid binding expressed in Centiloids

Authors: Christopher C. Rowe, Vincent Doré, Gareth Jones, David Baxendale, Rachel S. Mulligan, Santiago Bullich, Andrew W. Stephens, Susan De Santi, Colin L. Masters, Ludger Dinkelborg, Victor L. Villemagne

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2017

Abstract

Purpose

The Centiloid (CL) method enables quantitative values from Aβ-amyloid (Aβ) imaging to be expressed in a universal unit providing pathological, diagnostic and prognostic thresholds in clinical practice and research and allowing integration of multiple tracers and methods. The method was developed for ¹¹C-PiB scans with zero CL set as the average in young normal subjects and 100 CL the average in subjects with mild Alzheimer’s disease (AD). The method allows derivation of equations to convert the uptake value of any tracer into the same standard CL units but first requires head-to-head comparison with ¹¹C-PiB results. We derived the equation to express ¹⁸F-florbetaben (FBB) binding in CL units.

Methods

Paired PiB and FBB PET scans were obtained in 35 subjects. including ten young normal subjects aged under 45 years (33 ± 8 years). FBB images were acquired from 90 to 110 min after injection. Spatially normalized images were analysed using the standard CL method (SPM8 coregistration of PET data to MRI data and the MNI-152 atlas) and standard CL regions (cortex and whole cerebellum downloaded from http://www.gaain.org).

Results

FBB binding was strongly correlated with PiB binding (R ² = 0.96, SUVR_FBB = 0.61 × SUVR_PiB + 0.39). The equation to derive CL values from FBB SUVR was CL units = 153.4 × SUVR_FBB − 154.9. The CL value in the young normal subjects was −1.08 ± 6.81 for FBB scans compared to −0.32 ± 3.48 for PiB scans, giving a variance ratio of 1.96 (SD_{FBB CL}/SD_{PiB CL}).

Conclusions

¹⁸F-FBB binding is strongly correlated with PiB binding and FBB results can now be expressed in CL units.

Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733–40. doi:10.2967/jnumed.110.076315.PubMed

Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78. doi:10.1016/S1474-4422(12)70142-4.CrossRefPubMed

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35. doi:10.1016/S1474-4422(08)70001-2.CrossRefPubMed

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718–25. doi:10.1212/01.wnl.0000261919.22630.ea.CrossRefPubMed

Thurfjell L, Lundqvist R, Buckley C, Smith A, Sherwin P. Automated quantification of [18F]flutemetamol data - comparison with standard of truth based on histopathology. J Nucl Med. 2013;54 Suppl 2:302.

Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, et al. PET quantification of 18F-florbetaben binding to beta-amyloid deposits in human brains. J Nucl Med. 2013;54:723–31. doi:10.2967/jnumed.112.107185.CrossRefPubMed

Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70–7. doi:10.2967/jnumed.112.109009.CrossRefPubMed

Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959–72.PubMed

Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25:1528–47.CrossRefPubMed

10.

Mourik JE, Lubberink M, Schuitemaker A, Tolboom N, van Berckel BN, Lammertsma AA, et al. Image-derived input functions for PET brain studies. Eur J Nucl Med Mol Imaging. 2009;36:463–71.CrossRefPubMed

11.

Tolboom N, Yaqub M, Boellaard R, Luurtsema G, Windhorst AD, Scheltens P, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2009;36:1629–38. doi:10.1007/s00259-009-1129-6.CrossRefPubMedPubMedCentral

12.

Zwan MD, Ossenkoppele R, Tolboom N, Beunders AJ, Kloet RW, Adriaanse SM, et al. Comparison of simplified parametric methods for visual interpretation of 11C-Pittsburgh compound-B PET images. J Nucl Med. 2014;55:1305–7. doi:10.2967/jnumed.114.139121.CrossRefPubMed

13.

Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–52.CrossRefPubMed

14.

Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11:1050–68. doi:10.1016/j.jalz.2014.09.004.CrossRefPubMed

15.

Villemagne VL, O’Keefe G, Mulligan RS, Rowe CC. Quantitative approaches to amyloid imaging. Methods Mol Biol. 2011;680:201–25. doi:10.1007/978-1-60761-901-7_14.CrossRefPubMed

16.

Yaqub M, Boellaard R, van Berckel BN, Tolboom N, Luurtsema G, Dijkstra AA, et al. Evaluation of tracer kinetic models for analysis of [18F]FDDNP studies. Mol Imaging Biol. 2009;11:322–33. doi:10.1007/s11307-009-0208-1.CrossRefPubMedPubMedCentral

17.

Carrillo MC, Rowe CC, Szoeke C, Masters CL, Ames D, O’Meara T, et al. Research and standardization in Alzheimer’s trials: reaching international consensus. Alzheimers Dement. 2013;9:160–8. doi:10.1016/j.jalz.2012.10.006.CrossRefPubMed

18.

Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e1–1-15.e4. doi:10.1016/j.jalz.2014.07.003.CrossRef

19.

Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. doi:10.1016/S1474-4422(13)70044-9.CrossRefPubMed

20.

Jack CR Jr, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, et al. Brain beta-amyloid load approaches a plateau. Neurology. 2013;80:890–6. doi:10.1212/WNL.0b013e3182840bbe.CrossRefPubMedPubMedCentral

21.

Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem. 2005;48:5980–8. doi:10.1021/jm050166g.CrossRefPubMedPubMedCentral

22.

Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39:983–9. doi:10.1007/s00259-012-2088-x.CrossRefPubMed

23.

Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben ((18)F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35. doi:10.1016/S1474-4422(11)70077-1.CrossRefPubMed

24.

Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210–7. doi:10.2967/jnumed.111.089730.CrossRefPubMed

25.

Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Chetelat G, Raniga P, et al. (18)F-florbetaben Abeta imaging in mild cognitive impairment. Alzheimers Res Ther. 2013;5:4. doi:10.1186/alzrt158.CrossRefPubMedPubMedCentral

26.

Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, et al. Abeta imaging with 18F-florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2015;86:431–6. doi:10.1136/jnnp-2014-308094.CrossRefPubMed

27.

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 2015;11:964–74. doi:10.1016/j.jalz.2015.02.004.CrossRefPubMed

28.

Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41:1398–407. doi:10.1007/s00259-014-2753-3.CrossRefPubMedPubMedCentral

Title: 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids
Authors: Christopher C. Rowe
Vincent Doré
Gareth Jones
David Baxendale
Rachel S. Mulligan
Santiago Bullich
Andrew W. Stephens
Susan De Santi
Colin L. Masters
Ludger Dinkelborg
Victor L. Villemagne
Publication date: 01-11-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3749-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

¹⁸F-Florbetaben PET beta-amyloid binding expressed in Centiloids

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2017

Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET

Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma

A rare case of thymoma first detected on gallium-68 PSMA PET/CT

The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma

Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial

Elevated tumor-to-liver uptake ratio (TLR) from 18F–FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection